TaoWeave, Inc. (TWAV): Nasdaq/NYSE listing notice — Oblong receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period to March 19, 2024

TaoWeave, Inc.

Nasdaq notified Oblong that its common stock closing bid price was below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until March 19, 2024, to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant by March 19, 2024, Oblong may qualify for a second 180-day compliance period.
Stock continues trading on Nasdaq Capital Market under symbol OBLG; delisting if not cured after possible appeal.
Company intends to monitor bid price and consider available options to regain compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

TaoWeave, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

September 21, 2023, Oblong, Inc., a Delaware corporation (the “ Company ”), received written notice (the " Notice ") from the Nasdaq Stock Market, LLC (" Nasdaq ") indicating that the bid price for the Company's common stock (the "Common Stock"), for the last 30 consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company is not in compliance with the $1.00 minimum bid price requirement for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no effect at this time of the Common Stock, which

View on SEC.gov

Browse all listing & compliance notices →

TaoWeave, Inc. filing history →

Source: SEC EDGAR

accession 0000746210-23-000075

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.